Nature Biotechnology’s annual survey highlights academic startups that are, among other things, designing circular RNA therapeutics, tackling cancer with arenaviruses, creating psychedelics without the trip, editing genes and cells in vivo, harnessing the power of autoantibodies and editing the epigenome.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy
Signal Transduction and Targeted Therapy Open Access 23 December 2025
-
Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24
Epigenetics Communications Open Access 03 June 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
28 December 2022
In the version of this article initially published, the name of Angelo Lombardo appeared incorrectly as Alberto Lombardo, and has now been amended in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M., Garber, K., Landhuis, E. et al. Nature Biotechnology’s academic spinouts 2021. Nat Biotechnol 40, 1551–1562 (2022). https://doi.org/10.1038/s41587-022-01530-9
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-022-01530-9
This article is cited by
-
Meeting report on the round table discussions ‘epigenetics and society’ CLEPIC24
Epigenetics Communications (2025)
-
Scarless circular mRNA-based CAR-T cell therapy elicits superior antitumor efficacy
Signal Transduction and Targeted Therapy (2025)
